ArticleOpen veterinary journal2025
Changes in the M1/M2 ratio due to andrographolide therapy for deep endometriosis: An experimental study using a BALB/C endometriosis model.
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Andrographolide is a compound that serves as an anti-inflammatory agent. M2 macrophages promote the disease, while M1 macrophages inhibit endometriosis progression. Aim: Andrographolide can modify the M1/M2 ratio, aligning with the pattern observed with standard treatment for deep endometriosis. Methods: This experimental study used a post-test-only research design with a control group of 42 female Balb/C divided into 6 groups. Mice in group N (normal), normal control (KN) endometriosis (END) without therapy, while the positive control (KP) group received endometriosis + dienogest, group (P1) END and 0.05 mg/kg BW andrographolide (AND), group (P2) END + 0.1 mg/kg BW AND, group (P3) (END + 0.2 mg/kg BW AND. CD86 (M1) macrophages, while CD163 (M2) macrophages examine the number of M1 and M2 cells via flow cytometry in a specific color. Results: There was a significant difference in M1, which was higher than M2 in the AND group, compared with KP. The number of M2 macrophages in the P2 group was significantly lower than that in the KN group. Similarly, the number of M2 macrophages in the P3 group was significantly lower than that in the KN group. Conclusion: M1 was superior to M2 in the andrographolide group and exhibited a similar trend in the visanne group. This study serves as a preliminary investigation using experimental animals and can be further developed as a foundation for research on andrographolide as an alternative therapy for endometriosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.